Pfizer says potential RSV vaccine 85% effective in late-stage trial 0 25.08.2022 19:44 United Press International (UPI.com) Pfizer said on Thursday that its potential vaccine for respiratory syncytial virus was more than 85% effective in a Phase 3 trial for preventing lower respiratory tract illness in older adults. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
